HC Wainwright Reaffirms “Buy” Rating for InflaRx (NASDAQ:IFRX)

HC Wainwright reaffirmed their buy rating on shares of InflaRx (NASDAQ:IFRX) in a research note issued to investors on Monday,Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock. HC Wainwright also issued estimates for InflaRx’s Q4 2024 earnings at ($0.31) EPS, FY2024 earnings at ($1.05) EPS, FY2025 earnings at ($1.16) EPS and FY2026 earnings at ($1.13) EPS.

InflaRx Trading Up 18.7 %

NASDAQ:IFRX opened at $2.03 on Monday. The firm has a fifty day simple moving average of $1.53 and a 200-day simple moving average of $1.51. InflaRx has a 12 month low of $1.17 and a 12 month high of $2.44.

Institutional Investors Weigh In On InflaRx

An institutional investor recently raised its position in InflaRx stock. Ikarian Capital LLC raised its holdings in shares of InflaRx (NASDAQ:IFRX) by 2.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 704,987 shares of the company’s stock after acquiring an additional 16,383 shares during the period. Ikarian Capital LLC owned approximately 1.20% of InflaRx worth $1,086,000 at the end of the most recent quarter. 42.39% of the stock is owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.